Drugs / TIOMOLIBDATE CHOLINE
TIOMOLIBDATE CHOLINE
also known as
ALXN1840 · ATN-224 · Bis-Choline Tetrathiomolybdate · formerly WTX101 · Choline tetrathiomolybdate · WTX-101
Small molecule targets SOD1 via inhibition
Trials 19 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT04610580 | Jan → Mar 2021 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04526210 | Oct 2020 → May 2021 | Wilson disease | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04560816 | Jul 2020 → Mar 2021 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04526197 | Jul → Nov 2020 | Wilson disease | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04594252 | Jul → Nov 2020 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05303324 | Jul → Oct 2019 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05641311 | Feb → May 2019 | Wilson disease | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05319912 | Apr → May 2014 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05319899 | Jan → Mar 2014 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00352742 | Jun 2006 → Sep 2008 | plasma cell myeloma | Attenuon | Terminated | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT04422431 | Dec 2020 → May 2022 | Wilson disease | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04573309 | Sep 2020 → Jun 2022 | Wilson disease | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02273596 | Nov 2014 → Oct 2016 | Wilson disease | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00674557 | Jun 2008 → Mar 2009 | breast cancer | Cancer Research UK | Terminated | No outcome recorded |
| Phase 2 | NCT00405574 | Nov 2006 → Jun 2008 | prostate cancer | Attenuon | Unknown | No outcome recorded |
| Phase 2 | NCT00383851 | Sep 2006 → Sep 2008 | melanoma | Attenuon | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05047523 | Sep 2021 → Jun 2023 | Wilson disease | Alexion Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT03403205 | Feb 2018 → Jun 2023 | Wilson disease | Alexion Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05686564 | — | Wilson disease | Alexion Pharmaceuticals, Inc. | No longer available | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TIOMOLIBDATE CHOLINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594259 ↗ |
| Known as | ALXN1840 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05303324 ↗ |
| Known as | ATN-224 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00383851 ↗ |
| Known as | Bis-Choline Tetrathiomolybdate | “Bis-choline tetrathiomolybdate (WTX101) is an oral first-in-class copper-protein-binding molecule that targets hepatic intracellular copper and reduces plasma...” PMID 28988934 ↗ Oct 2017 |
| Known as | Choline tetrathiomolybdate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594259 ↗ |
| Known as | formerly WTX101 | “formerly WTX101” NCT04573309 ↗1“formerly WTX101” NCT04594252 ↗ |
| Known as | WTX-101 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594259 ↗ |
| Action | Inhibit | “SOD1 inhibitor ATN-224” NCT00674557 ↗ |
| Modality | Small molecule | “ATN-224 is a small molecule that has been shown in pre-clinical studies to be antiangiogenic.” NCT00352742 ↗ |
| Route | Oral | “orally active” NCT00383851 ↗ |
| Target | SOD1 | “SOD1 inhibitor ATN-224” NCT00674557 ↗ |